TORL-1-23 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This TORL-1-23 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 4 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether TORL-1-23 can convert its Not disclosed profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | TORL-1-23 (query alias: TORL-1-23) |
|---|---|
| Modality / target | Not disclosed; Not disclosed; Not disclosed |
| Highest global status | Phase 2 |
| Originator | Not disclosed |
| Active developers | Not disclosed |
The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06690775 | Phase 2 | Recruiting | 230 | To assess the efficacy of TORL-1-23 as a monotherapy in women with advanced PROC expressing CLDN6 |
| NCT07322094 | Phase 1/2 | Recruiting | 60 | Characterize the safety and feasibility of TORL-1-23 in combination with chemotherapy by analyzing the incidence of treatment emergent adverse events and serious adverse events. |
| NCT05103683 | Phase 1 | Recruiting | 90 | Incidence and severity of adverse events and serious adverse events |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
1074P - Claudin- 6 (CLDN6) is a therapeutic target in ovarian cancer (OC): Emerging results from the CATALINA 1 (CAT1) study
Phase 1; n=130; evaluation: Positive. Reported fields: AE(G3+) = neutropenia, anemia, fatigue, abdominal pain, hypokalemia ; AE(G3+) = neutropenia, anemia, fatigue, abdominal pain, hypokalemia
721MO - Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors
Phase 1; n=68; evaluation: Positive. Reported fields: TRAE = 85 % ; TRAE = G1/2 TRAEs (>20%) included fatigue (42%), peripheral neuropathy (40%), alopecia (38%), nausea (31%), anemia (31%), WBC count decrease (23%), and arthralgia (23%). The most common (≥10%) G3+ TRAE was neutropenia (23%). % ; TRAE = G1/2 TRAEs (>20%) included fatigue (42%), peripheral neuropathy (40%), alopecia (38%), nausea (31%), anemia (31%), WBC count decrease (23%), and arthralgia (23%). The most common (≥10%) G3+ TRAE was neutropenia (23%). %
First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Phase 1; n=30; evaluation: Positive. Reported fields: DLT = No DLTs were observed at doses ≤2.4 mg/kg ; DLT = No DLTs were observed at doses ≤2.4 mg/kg ; DLT = No DLTs were observed at doses ≤2.4 mg/kg
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
TORL-1-23 addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Not disclosed—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 0 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| No matched asset transaction returned. | |||
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 4 August 2026. Counts and status fields may change as source records update.
